Market Pulse Archives

Oct. 29, 2018, 7:09 a.m. EDT

Dicerna's stock rockets after licensing, research collaboration with Eli Lilly

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Dicerna Pharmaceuticals Inc. (DRNA)
  • X
    Eli Lilly & Co. (LLY)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

Shares of Dicerna Pharmaceuticals Inc. /zigman2/quotes/203776010/composite DRNA +1.28% rocketed 42% in premarket trade Monday, after the company said it will receive an upfront payment of $100 million as part of a licensing and research collaboration with Eli Lilly & Co. /zigman2/quotes/200106384/composite LLY +1.11% , to develop new medicines in the areas of cardio-metabolic disease, neurodegeneration and pain. Eli Lilly's stock was still inactive ahead of the open. Under terms of the deal, Eli Lilly has also made an equity investment of $100 million at a premium, and Dicerna will be eligible to receive up to $350 million per target in development and commercialization milestones. ""We are excited to collaborate with Dicerna and utilize their RNAi expertise to study targets that up until now have proven to be very technically challenging," said Eli Lilly Chief Scientific Officer Daniel Skovronsky. Dicerna shares have rallied 44% year to date through Friday, while Lilly's stock has climbed 26% and the S&P 500 /zigman2/quotes/210599714/realtime SPX -1.12% has slipped 0.6%.

/zigman2/quotes/203776010/composite
US : U.S.: Nasdaq
$ 19.85
+0.25 +1.28%
Volume: 1.11M
Sept. 18, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$1.46 billion
Rev. per Employee
$79,180
loading...
/zigman2/quotes/200106384/composite
US : U.S.: NYSE
$ 154.17
+1.70 +1.11%
Volume: 13.21M
Sept. 18, 2020 4:04p
P/E Ratio
25.08
Dividend Yield
1.92%
Market Cap
$145.83 billion
Rev. per Employee
$634,842
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,319.47
-37.54 -1.12%
Volume: 4.09B
Sept. 18, 2020 5:15p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.